Clinical Trial: Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Brief Summary: Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Detailed Summary:

  1. Impending recurrent pterygium

  2. Anti-VEGF therapy

    • Bevacizumab
    • Subconjunctival injection
    • Suppress neovascularization

Sponsor: Ramathibodi Hospital

Current Primary Outcome: Severity of impending recurrent pterygium [ Time Frame: 3 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Visual analog scales [ Time Frame: 3 months ]
  • Adverse reactions [ Time Frame: 3 months ]


Original Secondary Outcome: Same as current

Information By: Ramathibodi Hospital

Dates:
Date Received: February 1, 2011
Date Started: January 2008
Date Completion:
Last Updated: February 1, 2011
Last Verified: January 2011